Julie L. Eiseman

Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients with Refractory Advanced Cancers

Ramesh K. Ramanathan, Donald L. Trump, Julie L. Eiseman et al. · Clinical Cancer Research · 2005 · 192 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD 2 F 1 mice and Fischer 344 rats

Merrill J. Egorin, Theodore Lagattuta, Deborah R. Hamburger et al. · Cancer Chemotherapy and Pharmacology · 2002 · 177 citations

Pharmacy, Pharmacokinetics, Pharmacology +8

Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats

Merrill J. Egorin, Zhi-Min Yuan, Dorothy L. Sentz et al. · Cancer Chemotherapy and Pharmacology · 1999 · 167 citations

Pharmacy, Pharmacokinetics, Pharmacology +5

Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma

William C. Zamboni, Anne Gervais, Merrill J. Egorin et al. · Cancer Chemotherapy and Pharmacology · 2004 · 164 citations

Medicine, Oncology, Pharmacology +12

Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts

Julie L. Eiseman, Jing Lan, Theodore Lagattuta et al. · Cancer Chemotherapy and Pharmacology · 2004 · 152 citations

Medicine, Pharmacokinetics, Pharmacology +11